NO2020021I1 - Brolucizumab - Google Patents

Brolucizumab

Info

Publication number: NO2020021I1
Authority: NO; Norway
Prior art keywords: brolucizumab
Prior art date: 2008-06-25

Application number

NO2020021C

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-25

Filing date

2020-08-04

Publication date

2020-08-04

2020-08-04 Application filed by Novartis Ag filed Critical Novartis Ag

2020-08-04 Publication of NO2020021I1 publication Critical patent/NO2020021I1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Dermatology (AREA)
Zoology (AREA)
Gynecology & Obstetrics (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)

NO2020021C 2008-06-25 2020-08-04 Brolucizumab NO2020021I1 (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US7569208P	2008-06-25	2008-06-25
US7569708P	2008-06-25	2008-06-25
US13321208P	2008-06-25	2008-06-25
US15504109P	2009-02-24	2009-02-24
PCT/CH2009/000220 WO2009155724A2 (en)	2008-06-25	2009-06-25	Stable and soluble antibodies inhibiting vegf

Publications (1)

Publication Number	Publication Date
NO2020021I1 true NO2020021I1 (no)	2020-08-04

Family

ID=41209803

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO2020021C NO2020021I1 (no)	2008-06-25	2020-08-04	Brolucizumab

Country Status (26)

Country	Link
US (6)	US8349322B2 (no)
EP (3)	EP3722310B1 (no)
JP (7)	JP5956752B2 (no)
KR (8)	KR102095257B1 (no)
CN (3)	CN104961828B (no)
AU (1)	AU2009264565C1 (no)
BR (1)	BRPI0914251B1 (no)
CA (2)	CA3020290A1 (no)
CL (1)	CL2010001544A1 (no)
CY (3)	CY1118829T1 (no)
DK (3)	DK2307454T3 (no)
ES (3)	ES2793008T3 (no)
FI (1)	FI3722310T3 (no)
HR (3)	HRP20170615T1 (no)
HU (4)	HUE032894T2 (no)
LT (4)	LT3722310T (no)
MX (3)	MX2011000011A (no)
NL (1)	NL301058I2 (no)
NO (1)	NO2020021I1 (no)
PH (1)	PH12015501593A1 (no)
PL (3)	PL2307454T3 (no)
PT (3)	PT2307454T (no)
RU (6)	RU2531523C3 (no)
SI (3)	SI3722310T1 (no)
WO (1)	WO2009155724A2 (no)
ZA (1)	ZA201008594B (no)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2004697A2 (en)	2006-04-07	2008-12-24	The Procter & Gamble Company	Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
DK2307454T3 (en)	2008-06-25	2017-04-24	Esbatech Alcon Biomed Res Unit	Stable and soluble antibodies that inhibit VEGF
ES2677003T3 (es)	2008-06-25	2018-07-27	Esbatech, An Alcon Biomedical Research Unit Llc	Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos
CN102076716A (zh)	2008-06-25	2011-05-25	艾斯巴技术,爱尔康生物医药研究装置有限责任公司	抑制TNFα的稳定和可溶的抗体
WO2010006454A2 (en) *	2008-06-30	2010-01-21	Esbatech, An Alcon Biomedical Research Unit Llc	Functionalized polypeptides
US8268314B2 (en)	2008-10-08	2012-09-18	Hoffmann-La Roche Inc.	Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102239181A (zh)	2009-02-24	2011-11-09	艾斯巴技术,爱尔康生物医药研究装置有限责任公司	用于鉴定细胞表面抗原的免疫结合剂的方法
WO2011005488A1 (en)	2009-06-22	2011-01-13	Amgen Inc.	Refolding proteins using a chemically controlled redox state
FI3660032T3 (fi)	2009-06-25	2025-12-18	Amgen Inc	Ei-nisäkäsperäisessä järjestelmässä ekspressoitujen proteiinien sieppauspuhdistusmenetelmiä
CA2815046C (en) *	2010-10-19	2019-05-14	Mayo Foundation For Medical Education And Research	Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
UY33679A (es)	2010-10-22	2012-03-30	Esbatech	Anticuerpos estables y solubles
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
SI2758432T1 (sl) *	2011-09-16	2019-07-31	Ucb Biopharma Sprl	Nevtralizirajoča protitelesa proti glavnim eksotoksinom TCDA in TCDB iz clostridium difficile
CA2850830A1 (en)	2011-10-13	2013-04-18	Aerpio Therapeutics, Inc.	Methods for treating vascular leak syndrome and cancer
WO2013113820A1 (en)	2012-02-02	2013-08-08	Esbatech - A Novartis Company Llc	Antibody-containing sustained-release formulation for ocular administration
SMT202100621T1 (it)	2012-07-13	2022-01-10	Roche Glycart Ag	Anticorpi bispecifici anti-vegf/anti-ang-2 e loro impiego nel trattamento delle malattie vascolari oculari
KR20150095684A (ko)	2012-12-18	2015-08-21	노파르티스 아게	히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
SI2956476T1 (sl)	2013-02-18	2020-03-31	Vegenics Pty Limited	Molekule za vezavo na ligande in uporabe le-teh
KR101541478B1 (ko)	2013-05-31	2015-08-05	동아쏘시오홀딩스 주식회사	항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
US10174102B2 (en)	2013-06-26	2019-01-08	Numab Innovation Ag	Antibody frameworks
KR20160030396A (ko)	2013-07-12	2016-03-17	옵쏘테크 코포레이션	안과적 질환을 치료하거나 예방하기 위한 방법
WO2015076425A1 (ja) *	2013-11-25	2015-05-28	リンク・ジェノミクス株式会社	新規モノクローナル抗体
CN106456757A (zh)	2014-05-12	2017-02-22	福尔密孔股份公司	含有vegf拮抗剂的预填充塑料注射器
US20170290876A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Compositions and methods for long acting proteins
EP3160991A2 (en)	2014-06-25	2017-05-03	Novartis AG	Compositions and methods for long acting proteins
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
GB201412658D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
KR102390359B1 (ko)	2014-09-29	2022-04-22	삼성전자주식회사	폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
TWI705827B (zh) *	2014-11-07	2020-10-01	瑞士商諾華公司	治療眼部疾病之方法
BR112017009728A2 (pt)	2014-11-10	2018-02-06	Genentech, Inc.	anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
WO2016120753A1 (en) *	2015-01-28	2016-08-04	Pfizer Inc.	Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
MX2017013113A (es)	2015-04-16	2018-07-06	Alder Biopharmaceuticals Inc	Anticuerpos anti-pacap y sus usos.
US10851399B2 (en) *	2015-06-25	2020-12-01	Native Microbials, Inc.	Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
GB201601077D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibody molecule
GB201601073D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies
JP2018525389A (ja)	2015-08-12	2018-09-06	ノバルティスアーゲー	眼障害を治療する方法
EP3368578B1 (en)	2015-10-30	2021-03-17	H. Hoffnabb-La Roche Ag	Anti-htra1 antibodies and methods of use thereof
US11136609B2 (en) *	2015-11-09	2021-10-05	National University Corporation Kyoto Institute Of Technology	Separating agent for human serum-derived IgG polyclonal antibodies, and method for separating human serum-derived IgG polyclonal antibodies using same
RU2734958C2 (ru)	2015-11-18	2020-10-26	Формикон Аг	Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
CA3005132A1 (en)	2015-11-18	2017-05-26	Sio2 Medical Products, Inc.	Coated syringe for ophthalmic formulations containing a vegf antagonist
MX2018006171A (es)	2015-11-18	2018-12-19	Formycon Ag	Jeringa de plastico precargada que contiene un antagonista de vegf.
GB201521389D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Method
GB201521382D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
EP3397276A4 (en)	2015-12-30	2019-12-18	Kodiak Sciences Inc.	ANTIBODIES AND CONJUGATES THEREOF
EP3401330A4 (en)	2016-01-06	2019-09-18	Order-Made Medical Research Inc.	ANTIBODY-BINDING BINDING BETWEEN VEGF AND NRP1
JP6910963B2 (ja)	2016-01-06	2021-07-28	株式会社オーダーメードメディカルリサーチ	高親和性抗ｖｅｇｆ抗体
USD789171S1 (en)	2016-01-21	2017-06-13	Nomis Llc	Right angle drive
EP3407868A1 (en)	2016-01-26	2018-12-05	Formycon AG	Liquid formulation of a vegf antagonist
WO2017136807A1 (en) *	2016-02-05	2017-08-10	The Board Of Regents Of The University Of Texas System	Egfl6 specific monoclonal antibodies and methods of their use
WO2017156423A2 (en) *	2016-03-11	2017-09-14	Integrated Biotherapeutics, Inc.	Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever
EP3222673A1 (de) *	2016-03-23	2017-09-27	LANXESS Deutschland GmbH	Metallazopigmente
CA3020839A1 (en) *	2016-04-15	2017-10-19	Alder Biopharmaceuticals, Inc.	Anti-pacap antibodies and uses thereof
PE20190448A1 (es)	2016-06-30	2019-03-29	Celltrion Inc	Formulacion farmaceutica liquida estable
CN109890982B (zh)	2016-07-08	2023-07-07	基因泰克公司	通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法
CN110382002B (zh) *	2017-03-09	2025-08-15	Mab发现股份有限公司	特异性结合人il-1r7的抗体
JOP20190245A1 (ar)	2017-04-20	2019-10-15	Novartis Ag	أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JP7282689B2 (ja)	2017-05-19	2023-05-29	カウンスィルオブサイエンティフィックアンドインダストリアルリサーチ	リフォールディングした組み換えヒト化ラニビズマブの製造方法
WO2018215580A1 (en)	2017-05-24	2018-11-29	Formycon Ag	Method for sterilizing prefilled plastic syringes containing a vegf antagonist
EP3630043A1 (en)	2017-05-24	2020-04-08	Formycon AG	Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
US20200171244A1 (en)	2017-05-24	2020-06-04	Sio2 Medical Products, Inc.	Sterilizable pharmaceutical package for ophthalmic formulations
KR102838340B1 (ko) *	2017-06-25	2025-07-24	시스트이뮨, 인코포레이티드	다중-특이적 항체 및 이들의 제조 및 사용 방법
WO2019020777A1 (en)	2017-07-26	2019-01-31	Formycon Ag	LIQUID FORMULATION OF A VEGF ANTAGONIST
CN111770999A (zh) *	2017-11-27	2020-10-13	4D分子治疗有限公司	腺相关病毒变体衣壳和用于抑制血管生成的应用
WO2019129677A1 (en)	2017-12-29	2019-07-04	F. Hoffmann-La Roche Ag	Anti-vegf antibodies and methods of use
US11078283B2 (en)	2018-01-17	2021-08-03	Apexigen, Inc.	Anti-PD-L1 antibodies and methods of use
KR20200140817A (ko)	2018-03-02	2020-12-16	코디악 사이언시스 인코포레이티드	Il-6 항체 그리고 이의 융합 작제물 및 접합체
KR20200131839A (ko)	2018-03-16	2020-11-24	노파르티스 아게	안질환의 치료 방법
WO2019195090A1 (en) *	2018-04-06	2019-10-10	Eli Lilly And Company	Ramucirumab for the treatment of cancers in pediatric patients
CA3108949A1 (en)	2018-08-30	2020-03-05	HCW Biologics, Inc.	Multi-chain chimeric polypeptides and uses thereof
WO2020047462A2 (en)	2018-08-30	2020-03-05	HCW Biologics, Inc.	Methods of treating aging-related disorders
CN120535649A (zh)	2018-08-30	2025-08-26	免疫生物公司	单链嵌合多肽和其用途
EP3849608B1 (en) *	2018-09-13	2023-08-30	The Board of Regents of The University of Texas System	Novel lilrb4 antibodies and uses thereof
CN120058958A (zh)	2018-09-24	2025-05-30	视点制药公司	靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
BR112021011290A2 (pt)	2018-12-18	2021-11-03	Novartis Ag	Formulação de solução de proteína contendo alta concentração de um anticorpo anti-vegf
USD907455S1 (en)	2019-05-21	2021-01-12	Nomis Llc	Right angle drive attachment
USD907456S1 (en)	2019-05-21	2021-01-12	Nomis Llc	Right angle drill attachment
CN114269903B (zh)	2019-06-21	2025-11-25	免疫生物公司	多链嵌合多肽和其用途
CA3149706A1 (en)	2019-09-13	2021-03-18	Novartis Ag	Methods for treating ocular diseases
CN114786731A (zh)	2019-10-10	2022-07-22	科达制药股份有限公司	治疗眼部病症的方法
AU2021217919A1 (en) *	2020-02-07	2022-09-29	Agency For Science, Technology And Research	Antigen-binding molecules against ALPPL2 and/or ALPP and uses thereof
KR20220140572A (ko)	2020-02-11	2022-10-18	에이치씨더블유 바이올로직스, 인크.	조절 t 세포를 활성화시키는 방법
JP2023513573A (ja)	2020-02-11	2023-03-31	エイチシーダブリューバイオロジックスインコーポレイテッド	加齢性および炎症性疾患を治療する方法
EP4103600A1 (en)	2020-02-11	2022-12-21	HCW Biologics, Inc.	Chromatography resin and uses thereof
US20230340112A1 (en) *	2020-02-28	2023-10-26	Apexigen, Inc.	Anti-sirpa antibodies and methods of use
KR20220152316A (ko) *	2020-03-12	2022-11-15	이뮨-온크 테라퓨틱스, 인코포레이티드	신규한 항-lilrb4 항체 및 유도체 생성물
PE20230252A1 (es)	2020-03-13	2023-02-07	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos de estos
US12497462B2 (en)	2020-04-29	2025-12-16	Immunitybio, Inc.	Anti-CD26 proteins and uses thereof
US12024545B2 (en)	2020-06-01	2024-07-02	HCW Biologics, Inc.	Methods of treating aging-related disorders
WO2021247003A1 (en)	2020-06-01	2021-12-09	HCW Biologics, Inc.	Methods of treating aging-related disorders
AU2021283199A1 (en)	2020-06-01	2023-01-05	Immunitybio, Inc.	Methods of treating aging-related disorders
MX2023000547A (es) *	2020-07-16	2023-02-13	Novartis Ag	Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
EP4228702A1 (en)	2020-10-15	2023-08-23	F. Hoffmann-La Roche AG	Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery
TW202237181A (zh)	2020-11-25	2022-10-01	瑞士商諾華公司	治療眼部疾病之方法
WO2022201084A1 (en)	2021-03-26	2022-09-29	Novartis Ag	Methods for treating ocular diseases
EP4329734A4 (en)	2021-04-26	2025-04-02	Celanese EVA Performance Polymers LLC	Implantable device for the delayed release of a macromolecular drug compound
EP4145456A1 (en)	2021-09-06	2023-03-08	Bayer AG	Prediction of a change related to a macular fluid
KR102809807B1 (ko)	2021-12-21	2025-05-16	한림대학교 산학협력단	항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
CA3245338A1 (en)	2022-03-02	2023-09-07	Immunitybio, Inc.	METHOD OF TREATMENT FOR PANCREATIC CANCER
TW202337496A (zh)	2022-03-17	2023-10-01	瑞士商諾華公司	治療新生血管性年齡相關性黃斑點退化之方法
CN117820474A (zh) *	2023-04-25	2024-04-05	南京贝思奥生物科技有限公司	改善眼部血管新生相关疾病的药物及其应用
CN117069848B (zh) *	2023-08-02	2025-02-28	武汉爱博泰克生物科技有限公司	抗人cd146兔单克隆抗体及其应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en)	1986-09-02	1989-11-14	Genex Corporation	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US5013653A (en)	1987-03-20	1991-05-07	Creative Biomolecules, Inc.	Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
US5132405A (en)	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
DE3853515T3 (de)	1987-05-21	2005-08-25	Micromet Ag	Multifunktionelle proteine mit vorbestimmter zielsetzung.
WO1989006692A1 (en)	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5147638A (en)	1988-12-30	1992-09-15	Oklahoma Medical Research Foundation	Inhibition of tumor growth by blockade of the protein C system
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
OA10149A (en)	1991-03-29	1996-12-18	Genentech Inc	Vascular endothelial cell growth factor antagonists
US6582959B2 (en)	1991-03-29	2003-06-24	Genentech, Inc.	Antibodies to vascular endothelial cell growth factor
JP4124480B2 (ja)	1991-06-14	2008-07-23	ジェネンテック・インコーポレーテッド	免疫グロブリン変異体
DE69233803D1 (de)	1992-10-28	2011-03-31	Genentech Inc	Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
IL117645A (en)	1995-03-30	2005-08-31	Genentech Inc	Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5730977A (en)	1995-08-21	1998-03-24	Mitsui Toatsu Chemicals, Inc.	Anti-VEGF human monoclonal antibody
US6258562B1 (en)	1996-02-09	2001-07-10	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
DE69726003T2 (de) *	1996-07-16	2004-08-26	Andreas Plückthun	Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
US6986890B1 (en)	1996-11-21	2006-01-17	Kyowa Hakko Kogyo Co., Ltd.	Anti-human VEGF receptor Flt-1 monoclonal antibody
US7365166B2 (en)	1997-04-07	2008-04-29	Genentech, Inc.	Anti-VEGF antibodies
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
NZ500078A (en) *	1997-04-07	2001-10-26	Genentech Inc	Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
ATE501170T1 (de) *	1997-04-07	2011-03-15	Genentech Inc	Verfahren zur herstellung humanisierter antikörper durch randomisierte mutagenese
WO2000034337A1 (en)	1998-12-10	2000-06-15	Tsukuba Research Laboratory, Toagosei Co., Ltd.	Humanized monoclonal antibodies against vascular endothelial cell growth factor
AU3737500A (en) *	1999-03-12	2000-09-28	Genentech Inc.	Method of preventing the death of retinal neurons and treating ocular diseases
HK1045700B (zh)	1999-04-28	2007-07-27	德克萨斯大学董事会	用於通过选择性抑制vegf来治疗癌症的组合物和方法
US6703020B1 (en)	1999-04-28	2004-03-09	Board Of Regents, The University Of Texas System	Antibody conjugate methods for selectively inhibiting VEGF
AU1097301A (en)	1999-10-22	2001-05-08	Scripps Research Institute, The	Humanization of non-human, mammalian antibodies
CA2396534C (en)	1999-12-28	2012-10-02	Esbatech Ag	Intrabodies with defined framework that is stable in a reducing environment and applications thereof
GB0013810D0 (en)	2000-06-06	2000-07-26	Celltech Chiroscience Ltd	Biological products
US7667004B2 (en)	2001-04-17	2010-02-23	Abmaxis, Inc.	Humanized antibodies against vascular endothelial growth factor
DE10201450B4 (de)	2002-01-16	2004-09-02	Infineon Technologies Ag	Carry-Skip-Addierer für verschlüsselte Daten
US6576941B1 (en)	2002-02-20	2003-06-10	Samsung Electronics Co., Ltd.	Ferroelectric capacitors on protruding portions of conductive plugs having a smaller cross-sectional size than base portions thereof
CN1187373C (zh) *	2002-03-20	2005-02-02	上海中信国健药业有限公司	人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物
CA2492671C (en)	2002-03-22	2012-04-17	Aprogen, Inc.	Humanized antibody and process for preparing same
DK1506236T3 (da)	2002-05-22	2013-03-04	Esbatech A Novartis Co Llc	Immunglobulin-frameworks, der udviser forbedret stabilitet i det intracellulære miljø og fremgangsmåder til identifikation deraf
EP1539947A4 (en) *	2002-08-15	2006-09-06	Epitomics Inc	HUMANIZED RABBIT ANTIBODIES
US20050186208A1 (en)	2003-05-30	2005-08-25	Genentech, Inc.	Treatment with anti-VEGF antibodies
US20050048578A1 (en) *	2003-06-26	2005-03-03	Epitomics, Inc.	Methods of screening for monoclonal antibodies with desirable activity
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) *	2003-11-01	2005-05-19	Genentech, Inc.	Anti-vegf antibodies
US7758859B2 (en)	2003-08-01	2010-07-20	Genentech, Inc.	Anti-VEGF antibodies
JP2007520991A (ja) *	2003-08-07	2007-08-02	エピトミクスインコーポレーティッド	ウサギ単クローン抗体をヒト型化する方法
AU2005269265B2 (en)	2004-08-02	2012-01-12	Zenyth Operations Pty Ltd	A method of treating cancer comprising a VEGF-B antagonist
PT1802334E (pt)	2004-10-21	2012-11-28	Genentech Inc	Método para tratamento de doenças neovasculares intraoculares
US7462697B2 (en) *	2004-11-08	2008-12-09	Epitomics, Inc.	Methods for antibody engineering
US7431927B2 (en)	2005-03-24	2008-10-07	Epitomics, Inc.	TNFα-neutralizing antibodies
KR20080068004A (ko) *	2005-08-15	2008-07-22	아라나 테라퓨틱스 리미티드	뉴 월드 영장류 구조형성영역을 가진 조작 항체
AR059066A1 (es)	2006-01-27	2008-03-12	Amgen Inc	Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007140534A1 (en) *	2006-06-08	2007-12-13	Csl Limited	Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
DK2046382T3 (en)	2006-07-10	2016-12-12	Esbatech Alcon Biomed Res Unit	scFv Antibodies which passes through the epithelial and / or endothelial layer
AU2007323925A1 (en)	2006-11-10	2008-05-29	Genentech, Inc.	Method for treating age-related macular degeneration
US7553486B2 (en)	2006-11-13	2009-06-30	Paul Theodore Finger	Anti-VEGF treatment for radiation-induced vasculopathy
WO2008077077A2 (en)	2006-12-19	2008-06-26	Genentech, Inc.	Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
IN2009DN05758A (no)	2007-03-12	2015-07-24	Esbatech Ag
MX2009013137A (es)	2007-06-06	2010-04-30	Domantis Ltd	Metodos para seleccionar polipeptidos resistentes a la proteasa.
JP2010528647A (ja)	2007-06-06	2010-08-26	ドマンティスリミテッド	ポリペプチド、抗体可変ドメインおよびアンタゴニスト
NZ581468A (en)	2007-06-25	2012-09-28	Esbatech Alcon Biomed Res Unit	Methods of modifying antibodies, and modified antibodies with improved functional properties
RU2010102064A (ru)	2007-06-25	2011-07-27	Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк (Ch)	Способ конструирования, основанный на определении последовательностей, способ оптимизации одноцепочечных антител
CA3053675A1 (en) *	2008-03-26	2009-10-01	Epitomics, Inc.	Anti-vegf antibody
WO2009155725A1 (en)	2008-06-25	2009-12-30	Esbatech, An Alcon Biomedical Research Unit Llc	Solubility optimization of immunobinders
DK2307454T3 (en) *	2008-06-25	2017-04-24	Esbatech Alcon Biomed Res Unit	Stable and soluble antibodies that inhibit VEGF
ES2677003T3 (es) *	2008-06-25	2018-07-27	Esbatech, An Alcon Biomedical Research Unit Llc	Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos
US8697074B2 (en) *	2008-07-10	2014-04-15	Esbatech, An Alcon Biomedical Research Unit Llc	Methods and compositions for enhanced delivery of macromolecules
CA2777527C (en) *	2009-12-23	2020-06-23	Esbatech, An Alcon Biomedical Research Unit Llc	Method for decreasing immunogenicity

2009
- 2009-06-25 DK DK09768693.5T patent/DK2307454T3/en active
- 2009-06-25 WO PCT/CH2009/000220 patent/WO2009155724A2/en not_active Ceased
- 2009-06-25 PL PL09768693T patent/PL2307454T3/pl unknown
- 2009-06-25 HU HUE09768693A patent/HUE032894T2/hu unknown
- 2009-06-25 KR KR1020187024733A patent/KR102095257B1/ko active Active
- 2009-06-25 KR KR1020197022648A patent/KR102157097B1/ko active Active
- 2009-06-25 ES ES17151756T patent/ES2793008T3/es active Active
- 2009-06-25 SI SI200932208T patent/SI3722310T1/sl unknown
- 2009-06-25 KR KR1020187000324A patent/KR20180005753A/ko not_active Abandoned
- 2009-06-25 HR HRP20170615TT patent/HRP20170615T1/hr unknown
- 2009-06-25 SI SI200931647A patent/SI2307454T1/sl unknown
- 2009-06-25 MX MX2011000011A patent/MX2011000011A/es active IP Right Grant
- 2009-06-25 JP JP2011515049A patent/JP5956752B2/ja active Active
- 2009-06-25 RU RU2011102583A patent/RU2531523C3/ru active
- 2009-06-25 DK DK17151756.8T patent/DK3216803T3/da active
- 2009-06-25 CA CA3020290A patent/CA3020290A1/en active Pending
- 2009-06-25 HU HUE17151756A patent/HUE050230T2/hu unknown
- 2009-06-25 AU AU2009264565A patent/AU2009264565C1/en active Active
- 2009-06-25 PT PT97686935T patent/PT2307454T/pt unknown
- 2009-06-25 MX MX2013004871A patent/MX347972B/es unknown
- 2009-06-25 LT LTEP20158159.2T patent/LT3722310T/lt unknown
- 2009-06-25 ES ES20158159T patent/ES2998307T3/es active Active
- 2009-06-25 LT LTEP09768693.5T patent/LT2307454T/lt unknown
- 2009-06-25 KR KR1020157032314A patent/KR101671886B1/ko active Active
- 2009-06-25 HR HRP20241467TT patent/HRP20241467T1/hr unknown
- 2009-06-25 CN CN201510205513.0A patent/CN104961828B/zh active Active
- 2009-06-25 EP EP20158159.2A patent/EP3722310B1/en active Active
- 2009-06-25 HU HUE20158159A patent/HUE068894T2/hu unknown
- 2009-06-25 PT PT171517568T patent/PT3216803T/pt unknown
- 2009-06-25 KR KR1020117001961A patent/KR102013220B1/ko active Active
- 2009-06-25 CN CN201910338494.7A patent/CN110372792A/zh active Pending
- 2009-06-25 RU RU2014132888A patent/RU2588467C3/ru active Protection Beyond IP Right Term
- 2009-06-25 KR KR1020207026266A patent/KR102296443B1/ko active Active
- 2009-06-25 ES ES09768693.5T patent/ES2622470T3/es active Active
- 2009-06-25 MX MX2017006583A patent/MX392435B/es unknown
- 2009-06-25 EP EP17151756.8A patent/EP3216803B1/en active Active
- 2009-06-25 PT PT201581592T patent/PT3722310T/pt unknown
- 2009-06-25 CN CN200980124313.5A patent/CN102143976B/zh active Active
- 2009-06-25 EP EP09768693.5A patent/EP2307454B1/en active Active
- 2009-06-25 KR KR1020177012884A patent/KR101817284B1/ko active Active
- 2009-06-25 KR KR1020167030125A patent/KR101737466B1/ko active Active
- 2009-06-25 PL PL17151756T patent/PL3216803T3/pl unknown
- 2009-06-25 US US13/000,423 patent/US8349322B2/en active Active
- 2009-06-25 CA CA2727839A patent/CA2727839C/en active Active
- 2009-06-25 PL PL20158159.2T patent/PL3722310T3/pl unknown
- 2009-06-25 LT LTEP17151756.8T patent/LT3216803T/lt unknown
- 2009-06-25 BR BRPI0914251-7A patent/BRPI0914251B1/pt active IP Right Grant
- 2009-06-25 SI SI200932061T patent/SI3216803T1/sl unknown
- 2009-06-25 DK DK20158159.2T patent/DK3722310T3/da active
- 2009-06-25 FI FIEP20158159.2T patent/FI3722310T3/fi active
2010
- 2010-11-30 ZA ZA2010/08594A patent/ZA201008594B/en unknown
- 2010-12-23 CL CL2010001544A patent/CL2010001544A1/es unknown
2012
- 2012-12-07 US US13/708,575 patent/US9090684B2/en active Active
2013
- 2013-07-19 RU RU2013133802/10A patent/RU2013133802A/ru not_active Application Discontinuation
2014
- 2014-04-21 JP JP2014087194A patent/JP6100199B2/ja active Active
2015
- 2015-02-27 JP JP2015037794A patent/JP2015134792A/ja active Pending
- 2015-06-16 US US14/741,430 patent/US9873737B2/en active Active
- 2015-07-20 PH PH12015501593A patent/PH12015501593A1/en unknown
2016
- 2016-05-18 RU RU2016119152A patent/RU2648152C2/ru active
- 2016-12-28 JP JP2016255720A patent/JP6527128B2/ja active Active
2017
- 2017-04-12 CY CY20171100436T patent/CY1118829T1/el unknown
- 2017-11-16 US US15/814,784 patent/US10590193B2/en active Active
2018
- 2018-02-05 JP JP2018018375A patent/JP6821612B2/ja active Active
- 2018-02-16 RU RU2018105866A patent/RU2696972C1/ru active
2019
- 2019-05-13 JP JP2019090735A patent/JP6978468B2/ja active Active
- 2019-06-27 RU RU2019120079A patent/RU2747735C3/ru active
2020
- 2020-01-31 US US16/779,028 patent/US20200172608A1/en not_active Abandoned
- 2020-05-19 HR HRP20200814TT patent/HRP20200814T1/hr unknown
- 2020-06-05 CY CY20201100507T patent/CY1123028T1/el unknown
- 2020-07-23 LT LTPA2020004C patent/LTC2307454I2/lt unknown
- 2020-07-27 HU HUS2000028C patent/HUS2000028I1/hu unknown
- 2020-07-28 NL NL301058C patent/NL301058I2/nl unknown
- 2020-07-30 CY CY2020026C patent/CY2020026I2/el unknown
- 2020-08-04 NO NO2020021C patent/NO2020021I1/no unknown
2021
- 2021-11-11 JP JP2021184262A patent/JP7171877B6/ja active Active
2023
- 2023-02-07 US US18/165,845 patent/US20250066462A1/en active Pending

Also Published As

Publication number	Publication date
KR102157097B1 (ko)	2020-09-18
US9873737B2 (en)	2018-01-23
RU2747735C2 (ru)	2021-05-13
US10590193B2 (en)	2020-03-17
US8349322B2 (en)	2013-01-08
CN102143976A (zh)	2011-08-03
BRPI0914251B1 (pt)	2022-07-19
SI3216803T1 (sl)	2020-07-31
CL2010001544A1 (es)	2012-02-03
RU2648152C2 (ru)	2018-03-22
MX2011000011A (es)	2011-09-27
EP2307454B1 (en)	2017-01-18
CY2020026I1 (el)	2020-11-25
EP3216803B1 (en)	2020-03-11
RU2019120079A (ru)	2020-12-28
DK2307454T3 (en)	2017-04-24
HUE050230T2 (hu)	2020-11-30
HUS2000028I1 (hu)	2020-08-28
JP2018108081A (ja)	2018-07-12
HRP20170615T1 (hr)	2017-07-28
CY2020026I2 (el)	2020-11-25
AU2009264565A1 (en)	2009-12-30
JP2022020782A (ja)	2022-02-01
HRP20241467T1 (hr)	2025-01-03
KR20160128458A (ko)	2016-11-07
EP3216803A1 (en)	2017-09-13
RU2696972C1 (ru)	2019-08-07
ZA201008594B (en)	2012-02-29
RU2531523C2 (ru)	2014-10-20
LTC2307454I2 (lt)	2021-05-25
PL2307454T3 (pl)	2017-07-31
RU2531523C9 (ru)	2015-04-10
JP6100199B2 (ja)	2017-03-22
KR102296443B1 (ko)	2021-09-01
RU2014132888A (ru)	2015-12-10
NL301058I2 (nl)	2020-10-27
US20140004114A1 (en)	2014-01-02
JP2011525359A (ja)	2011-09-22
PT3722310T (pt)	2024-11-12
CY1118829T1 (el)	2018-01-10
JP2019162127A (ja)	2019-09-26
HUE068894T2 (hu)	2025-02-28
JP2014158491A (ja)	2014-09-04
LT3216803T (lt)	2020-06-10
KR20200108922A (ko)	2020-09-21
JP7171877B6 (ja)	2024-02-06
ES2998307T3 (en)	2025-02-19
CY1123028T1 (el)	2021-10-29
WO2009155724A2 (en)	2009-12-30
KR20180098705A (ko)	2018-09-04
DK3216803T3 (da)	2020-06-02
KR20150132602A (ko)	2015-11-25
DK3722310T3 (da)	2024-11-18
ES2793008T3 (es)	2020-11-12
US20200172608A1 (en)	2020-06-04
JP6821612B2 (ja)	2021-01-27
KR101671886B1 (ko)	2016-11-04
KR102013220B1 (ko)	2019-08-23
MX392435B (es)	2025-03-19
HK1150844A1 (en)	2012-01-13
CN102143976B (zh)	2015-11-25
RU2013133802A (ru)	2015-01-27
FI3722310T3 (fi)	2024-11-27
PT2307454T (pt)	2017-04-26
JP6527128B2 (ja)	2019-06-05
US20150274820A1 (en)	2015-10-01
LTPA2020004I1 (lt)	2020-08-10
EP3722310B1 (en)	2024-08-28
KR101817284B1 (ko)	2018-01-11
MX347972B (es)	2017-05-22
CN104961828A (zh)	2015-10-07
HUE032894T2 (hu)	2017-11-28
JP2017055774A (ja)	2017-03-23
NL301058I1 (no)	2020-07-31
RU2747735C3 (ru)	2022-05-04
RU2016119152A (ru)	2017-11-21
JP2015134792A (ja)	2015-07-27
PH12015501593A1 (en)	2015-12-14
AU2009264565C1 (en)	2022-01-27
US20120014958A1 (en)	2012-01-19
KR20190092630A (ko)	2019-08-07
LT2307454T (lt)	2017-05-25
HRP20200814T1 (hr)	2020-08-07
WO2009155724A3 (en)	2010-04-01
RU2019120079A3 (no)	2020-12-28
KR101737466B1 (ko)	2017-05-18
PL3216803T3 (pl)	2020-10-19
SI2307454T1 (sl)	2017-05-31
KR20170057462A (ko)	2017-05-24
RU2531523C3 (ru)	2022-05-04
PT3216803T (pt)	2020-06-16
RU2011102583A (ru)	2012-07-27
LT3722310T (lt)	2024-12-27
JP7171877B2 (ja)	2022-11-15
CA2727839C (en)	2018-11-20
CA2727839A1 (en)	2009-12-30
US9090684B2 (en)	2015-07-28
SI3722310T1 (sl)	2025-01-31
US20180072802A1 (en)	2018-03-15
PL3722310T3 (pl)	2025-01-20
BRPI0914251A2 (pt)	2021-01-05
JP6978468B2 (ja)	2021-12-08
KR20110028518A (ko)	2011-03-18
RU2588467C3 (ru)	2021-10-20
CN104961828B (zh)	2019-03-26
US20250066462A1 (en)	2025-02-27
AU2009264565B2 (en)	2014-05-08
EP2307454A2 (en)	2011-04-13
CA3020290A1 (en)	2009-12-30
CN110372792A (zh)	2019-10-25
KR20180005753A (ko)	2018-01-16
KR102095257B1 (ko)	2020-04-01
EP3722310A1 (en)	2020-10-14
ES2622470T3 (es)	2017-07-06
JP5956752B2 (ja)	2016-07-27

Publication	Publication Date	Title
DK2370462T3 (da)	2014-09-08	Glucagon-analoger
DK2342317T3 (da)	2013-03-18	Hængende-dråbe-plade
DE602009000234D1 (de)	2010-11-11	msignals
BRPI0907376A2 (pt)	2015-07-14	Fotobiorretador
EP2258938A4 (en)	2012-09-05	TYPE VEHICLE TO BE PROVIDED
EP2368526A4 (en)	2015-04-15	INSERTION TOOL FOR AN INTRAOCULAR LENS
BRPI0914649A2 (pt)	2015-07-07	Piprazolo-quinazolinas
EP2336764A4 (en)	2011-09-28	LIQUID CHROMATOGRAPH
DE602008003972D1 (de)	2011-01-27	Sitzrücklehnungsmechanismus
DK2336132T3 (da)	2014-04-07	Morpholinpurinderivat
DK2335031T3 (da)	2019-08-26	In-line-måler
EP2368115A4 (en)	2012-08-22	ANALYTE DETECTION TEST
EP2308156A4 (en)	2014-02-19	STEP ACTUATOR
DK2379557T3 (da)	2012-12-17	Aminopyrazol-forbindelse
DK2271613T3 (da)	2014-07-14	Hydroxymethylcyklohexylaminer
DE602008003970D1 (de)	2011-01-27	Strahlstromkalibriersystem
EP2257170A4 (en)	2011-08-03	TETRAHYDROFUROPYRIDONE
EP2248964A4 (en)	2011-08-31	DRILLING / TERMINAL DEVICE
BRPI0907522A2 (pt)	2019-09-24	biarlamidas
EP2360457A4 (en)	2014-08-27	Gas shutoff device
EP2318641A4 (en)	2015-12-09	TOOL FOR CENTERING FOR DRILLING ENCLOSURE
DE112009000183A5 (de)	2011-02-03	Sicherheitsvorreiber
EP2339366A4 (en)	2013-01-30	DEVICE FOR OPTICAL DISTANCE MEASUREMENT
BRPI0909634A2 (pt)	2015-09-22	2-aminoquinolinas
DE602009000862D1 (de)	2011-04-28	Gehwagenbremse